Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 28 02:12PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.53 Insider Own2.11% Shs Outstand192.23M Perf Week-9.39%
Market Cap148.27M Forward P/E- EPS next Y-0.71 Insider Trans0.61% Shs Float188.17M Perf Month-27.92%
Income-100.69M PEG- EPS next Q-0.23 Inst Own21.05% Short Float / Ratio0.19% / 1.72 Perf Quarter-54.09%
Sales0.00M P/S- EPS this Y45.06% Inst Trans22.68% Short Interest0.35M Perf Half Y-58.31%
Book/sh0.75 P/B1.03 EPS next Y-4.40% ROA-45.99% Target Price3.87 Perf Year-43.29%
Cash/sh0.78 P/C0.99 EPS next 5Y21.22% ROE-56.56% 52W Range0.65 - 2.37 Perf YTD-49.59%
Dividend- P/FCF- EPS past 5Y28.66% ROI-69.89% 52W High-67.46% Beta1.07
Dividend %- Quick Ratio5.38 Sales past 5Y0.00% Gross Margin- 52W Low18.66% ATR0.06
Employees85 Current Ratio5.38 Sales Q/Q- Oper. Margin0.00% RSI (14)20.09 Volatility8.38% 7.33%
OptionableYes Debt/Eq0.05 EPS Q/Q5.87% Profit Margin- Rel Volume0.20 Prev Close0.79
ShortableYes LT Debt/Eq0.00 EarningsOct 31 AMC Payout- Avg Volume205.73K Price0.77
Recom1.67 SMA20-16.00% SMA50-30.48% SMA200-49.47% Volume31,568 Change-2.16%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
Nov-09-23 04:30PM
Nov-06-23 04:30PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Oct-27-23 04:30PM
02:00AM Loading…
Oct-16-23 02:00AM
Oct-05-23 04:30PM
Sep-05-23 04:30PM
Jul-31-23 04:25PM
Jul-25-23 04:30PM
Jul-19-23 04:30PM
Jul-10-23 04:30PM
Jun-16-23 04:30PM
Jun-08-23 04:30PM
Jun-06-23 05:00PM
05:30PM Loading…
May-10-23 05:30PM
May-09-23 04:30PM
May-04-23 04:30PM
Apr-19-23 05:09PM
Apr-12-23 04:30PM
Mar-24-23 04:30PM
Mar-13-23 01:30AM
Mar-07-23 04:30PM
Mar-02-23 05:30PM
Feb-27-23 01:30AM
Feb-21-23 04:30PM
Feb-10-23 04:30PM
Jan-23-23 04:30PM
Jan-04-23 04:30PM
01:30AM Loading…
Dec-23-22 01:30AM
Dec-08-22 04:30PM
Nov-22-22 04:30PM
Nov-09-22 01:30AM
Nov-03-22 04:30PM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Oct-03-22 04:30PM
Sep-21-22 05:45PM
Sep-07-22 04:30PM
Sep-02-22 04:30PM
Aug-10-22 04:50PM
Aug-01-22 04:30PM
Jul-27-22 04:30PM
Jul-20-22 04:30PM
Jun-28-22 06:15PM
Jun-16-22 01:30AM
Jun-09-22 02:55AM
Jun-07-22 04:30PM
May-17-22 04:30PM
May-12-22 04:30PM
May-04-22 07:30PM
May-02-22 05:00PM
Apr-25-22 07:30PM
Apr-21-22 04:30PM
Apr-14-22 04:30PM
Mar-14-22 04:30PM
Mar-11-22 04:30PM
Mar-09-22 04:30PM
Mar-03-22 04:15PM
Feb-24-22 04:30PM
Feb-22-22 04:30PM
Feb-14-22 04:30PM
Feb-09-22 04:30PM
Jan-21-22 04:30PM
Jan-18-22 05:38PM
Jan-12-22 04:30PM
Jan-07-22 01:30AM
Dec-20-21 04:15PM
Dec-10-21 04:30PM
Nov-24-21 01:30AM
Nov-04-21 04:30PM
Nov-01-21 03:34PM
Oct-29-21 05:07PM
Oct-27-21 03:35PM
Oct-26-21 04:15PM
Oct-12-21 04:30PM
Sep-08-21 04:00PM
Aug-31-21 01:30AM
Aug-20-21 04:15PM
Aug-09-21 04:30PM
Aug-06-21 04:30PM
Aug-02-21 04:15PM
Jul-26-21 04:30PM
Jul-07-21 04:30PM
Jun-15-21 04:30PM
Jun-02-21 01:30AM
May-19-21 04:30PM
May-17-21 04:30PM
May-05-21 05:00PM
May-03-21 01:30AM
Apr-29-21 01:30AM
Apr-28-21 04:30PM
Apr-02-21 04:30PM
Apr-01-21 06:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MORRIS TIMOTHY EDirectorAug 25Buy1.5212,00018,24012,000Aug 28 04:35 PM
SOLAND DANIEL BDirectorAug 01Buy1.6215,00024,30020,000Aug 03 04:40 PM
Mohideen PharisChief Medical OfficerMay 24Sale3.544691,66049,439Aug 14 04:32 PM